

David Dingli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1186019/david-dingli-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

526
papers

15,028
citations

59
h-index

110
g-index

548
ext. papers

17,691
ext. citations

4.5
avg, IF

6.14
L-index

#	Paper	IF	Citations
526	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008 , 111, 2516-20	2.2	1753
525	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. <i>Leukemia</i> , 2014 , 28, 1122-8	10.7	880
524	Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. <i>Journal of Clinical Oncology</i> , 2012 , 30, 989-95	2.2	582
523	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 360-76	6.4	341
522	Genetic progression and the waiting time to cancer. <i>PLoS Computational Biology</i> , 2007 , 3, e225	5	280
521	Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. <i>Blood</i> , 2004 , 103, 1641-6	2.2	272
520	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 381, 727-738	59.2	266
519	Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5008-14	2.2	252
518	Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 87-94	6.4	234
517	Remission of disseminated cancer after systemic oncolytic virotherapy. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 926-33	6.4	202
516	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 1095-110	6.4	199
515	Successful therapy must eradicate cancer stem cells. <i>Stem Cells</i> , 2006 , 24, 2603-10	5.8	193
514	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017 , 129, 2111-2119	2.2	181
513	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012 , 119, 2100-5	2.2	181
512	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. <i>Leukemia</i> , 2007 , 21, 529-34	10.7	168
511	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). <i>Leukemia</i> , 2010 , 24, 1934-9	10.7	166
510	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4319-24	2.2	146

509	Unexplained pulmonary hypertension in chronic myeloproliferative disorders. <i>Chest</i> , 2001 , 120, 801-8	5.3	145
508	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 12-8	6.4	141
507	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. <i>Blood</i> , 2012 , 119, 5397-404	2.2	125
506	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. <i>Bone Marrow Transplantation</i> , 2013 , 48, 557-61	4.4	124
505	Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4529-35	2.2	122
504	Immunoglobulin free light chains and solitary plasmacytoma of bone. <i>Blood</i> , 2006 , 108, 1979-83	2.2	122
503	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 59	7	115
502	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. <i>American Journal of Hematology</i> , 2008 , 83, 614-7	7.1	110
501	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012 , 119, 4860-7	2.2	108
500	Modeling of cancer virotherapy with recombinant measles viruses. <i>Journal of Theoretical Biology</i> , 2008 , 252, 109-22	2.3	103
499	Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 700-10	6.1	101
498	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 859-866	2.2	100
497	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016 , 22, 1411-1420	50.5	99
496	Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. <i>Cancer Gene Therapy</i> , 2010 , 17, 550-8	5.4	99
495	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011 , 25, 689-96	10.7	94
494	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. <i>Leukemia</i> , 2017 , 31, 2791-2798	10.7	92
493	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012 , 118, 1585-92	6.4	92
492	(A)symmetric stem cell replication and cancer. <i>PLoS Computational Biology</i> , 2007 , 3, e53	5	92

491	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 578-598	6.4	88
490	Mathematical modeling of cancer radiotherapy. <i>Mathematical Biosciences</i> , 2006 , 199, 55-78	3.9	87
489	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014 , 124, 907-12	2.2	83
488	Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1131-8	6.4	83
487	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. <i>JAMA Oncology</i> , 2017 , 3, 1257-1265	13.4	82
486	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1054-81	6.4	81
485	Genetically targeted radiotherapy for multiple myeloma. <i>Blood</i> , 2003 , 102, 489-96	2.2	80
484	How we manage autologous stem cell transplantation for patients with multiple myeloma. <i>Blood</i> , 2014 , 124, 882-90	2.2	79
483	Stochastic dynamics of hematopoietic tumor stem cells. <i>Cell Cycle</i> , 2007 , 6, 461-6	4.7	79
482	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2015 , 5, e296	7	73
481	Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 384-8		73
480	In vivo imaging and tumor therapy with the sodium iodide symporter. <i>Journal of Cellular Biochemistry</i> , 2003 , 90, 1079-86	4.7	72
479	Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. <i>British Journal of Cancer</i> , 2009 , 101, 1130-6	8.7	71
478	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017 , 31, 1562-1569	10.7	70
477	Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 587-96	6.4	70
476	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. <i>Blood Cancer Journal</i> , 2015 , 5, e364	7	70
475	Compartmental architecture and dynamics of hematopoiesis. <i>PLoS ONE</i> , 2007 , 2, e345	3.7	70
474	Proteasome inhibitor associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2016 , 91, E348-52	7.1	70

473	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018 , 8, 26	7	68
472	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1323-1329	2.2	68
471	Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. <i>American Journal of Roentgenology</i> , 2009 , 192, 279-87	5.4	66
470	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015 , 90, 181-6	7.1	60
469	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 531-536	10.7	60
468	Sodium iodide symporter (NIS)-mediated radiotherapy for pancreatic cancer. <i>American Journal of Roentgenology</i> , 2010 , 195, 341-9	5.4	59
467	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1302-7	4.4	58
466	Allometric scaling of the active hematopoietic stem cell pool across mammals. <i>PLoS ONE</i> , 2006 , 1, e2	3.7	57
465	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. <i>Blood</i> , 2006 , 107, 3384-8	2.2	56
464	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. <i>Leukemia</i> , 2016 , 30, 2208-2213	10.7	55
463	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. <i>Heart</i> , 2014 , 100, 383-8	5.1	52
462	Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. <i>Molecular Imaging and Biology</i> , 2006 , 8, 16-23	3.8	52
461	Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions. <i>ELife</i> , 2015 , 4,	8.9	52
460	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016 , 91, 1123-1128	7.1	52
459	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. <i>Blood Cancer Journal</i> , 2015 , 5, e310	7	51
458	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367	4.4	51
457	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. <i>American Journal of Hematology</i> , 2011 , 86, 640-5	7.1	51
456	Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. <i>Cancer</i> , 2006 , 106, 1985-9	6.4	51

455	Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. <i>Cancer Gene Therapy</i> , 2009 , 16, 873-82	5.4	50
454	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018 , 32, 2240-2249	10.7	49
453	Dynamics of mutant cells in hierarchical organized tissues. <i>PLoS Computational Biology</i> , 2011 , 7, e1002290	3.9	49
452	The ecology of cancer from an evolutionary game theory perspective. <i>Interface Focus</i> , 2014 , 4, 20140019	3.9	47
451	Second auto-SCT for treatment of relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2013 , 48, 568-73	4.4	47
450	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017 , 92, 668-673	7.1	46
449	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1198-1204	2.2	46
448	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. <i>Leukemia</i> , 2017 , 31, 130-135	10.7	46
447	Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. <i>Cancer</i> , 2006 , 106, 623-30	6.4	46
446	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 187-194	7.1	45
445	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 156, 326-33	4.5	45
444	Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. <i>Haematologica</i> , 2010 , 95, 900-7	6.6	45
443	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 908-917	6.4	43
442	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018 , 97, 1417-1425	3	43
441	Natural history of t(11;14) multiple myeloma. <i>Leukemia</i> , 2018 , 32, 131-138	10.7	43
440	Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. <i>American Journal of Kidney Diseases</i> , 2005 , 46, 278-82	7.4	43
439	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. <i>Leukemia</i> , 2016 , 30, 633-9	10.7	42
438	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, 1129-1134	7.1	42

437	Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. <i>Haemophilia</i> , 2002 , 8, 629-34	3.3	42
436	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016 , 6, e454	7	42
435	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017 , 129, 82-87	2.2	41
434	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018 , 25, 86-92	2.7	40
433	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016 , 91, 585-9	7.1	40
432	Neutral evolution in paroxysmal nocturnal hemoglobinuria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 18496-500	11.5	39
431	Relationship between depth of response and outcome in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4933-7	2.2	38
430	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 116	7	38
429	Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2005 , 130, 229-32	4.5	37
428	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1449-1455	4.4	37
427	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016 , 91, 984-8	7.1	37
426	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. <i>Leukemia</i> , 2018 , 32, 729-735	10.7	36
425	A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues. <i>Journal of the Royal Society Interface</i> , 2013 , 10, 20130349	4.1	35
424	Systemic amyloidosis from A (AA) to T (ATTR): a review. <i>Journal of Internal Medicine</i> , 2021 , 289, 268-292	10.8	35
423	Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 325, 157-66	3.4	34
422	Optimization of virotherapy for cancer. <i>Bulletin of Mathematical Biology</i> , 2010 , 72, 469-89	2.1	33
421	Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. <i>Internal Medicine</i> , 2004 , 43, 540-7	1.1	33
420	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 472-483	6.4	33

419	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 598-605	4.7	32
418	Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. <i>Leukemia</i> , 2019 , 33, 2695-2709	10.7	32
417	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e006588	3.9	31
416	A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. <i>Bone</i> , 2010 , 47, 12-22	4.7	31
415	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017 , 92, 50-55	7.1	30
414	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1354-1361	6.4	30
413	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019 , 33, 527-531	10.7	30
412	Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. <i>Clinical Cancer Research</i> , 2002 , 8, 3948-54	12.9	30
411	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017 , 31, 92-99	10.7	29
410	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 179-186	7.1	29
409	On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria. <i>Stem Cells</i> , 2007 , 25, 3081-4	5.8	29
408	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 644-654	2	29
407	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015 , 90, 981-5	7.1	28
406	Schnitzler syndrome: an under-diagnosed clinical entity. <i>Haematologica</i> , 2013 , 98, 1581-5	6.6	28
405	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , 2016 , 122, 2197-205	6.4	28
404	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016 , 6, e512	7	28
403	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017 , 49, 545-551	1.5	27
402	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020 , 4, 3509-3519	7.8	27

401	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019 , 187, 588-594	4.5	26
400	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. <i>Leukemia</i> , 2013 , 27, 2062-6	10.7	26
399	Interaction of measles virus vectors with Auger electron emitting radioisotopes. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 337, 22-9	3.4	26
398	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015 , 90, 524-8	7.1	25
397	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1020-1026	7.1	25
396	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014 , 89, 1051-4	7.1	25
395	On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population. <i>Journal of the Royal Society Interface</i> , 2013 , 10, 20120810	4.1	25
394	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. <i>Neurology</i> , 2010 , 74, 913-8	6.5	25
393	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. <i>Leukemia</i> , 2016 , 30, 1079-85	10.7	24
392	Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. <i>Gene Therapy</i> , 2012 , 19, 279-87	4	24
391	The emergence of tumor metastases. <i>Cancer Biology and Therapy</i> , 2007 , 6, 383-90	4.6	24
390	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014 , 124, 304-304	2.2	24
389	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017 , 7, e528	7	23
388	Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. <i>Gene Therapy</i> , 2012 , 19, 543-9	4	23
387	Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse. <i>Clinical Leukemia</i> , 2008 , 2, 133-139		23
386	Imatinib and type 2 diabetes. <i>Endocrine Practice</i> , 2007 , 13, 126-30	3.2	23
385	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403	4.5	23
384	Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. <i>British Journal of Cancer</i> , 2016 , 115, 195-202	8.7	23

383	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019 , 9, 32	7	22
382	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. <i>Leukemia</i> , 2015 , 29, 2033-8	10.7	22
381	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 55	7	22
380	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, 1146-1155	7.1	22
379	Ontogenic growth of the haemopoietic stem cell pool in humans. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2007 , 274, 2497-2501	4.4	22
378	Pyoderma gangrenosum in hematologic malignancies: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1346-1359	4.5	22
377	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1284-9	4.3	21
376	Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the "hot knees" sign differential diagnosis. <i>Skeletal Radiology</i> , 2014 , 43, 905-15	2.7	21
375	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014 , 92, 485-90	3.8	21
374	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020 , 27, 13-16	2.7	21
373	HIV-1 Activation of Innate Immunity Depends Strongly on the Intracellular Level of TREX1 and Sensing of Incomplete Reverse Transcription Products. <i>Journal of Virology</i> , 2018 , 92,	6.6	21
372	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1126-1132	4.4	20
371	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018 , 32, 712-718	10.7	20
370	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016 , 91, 473-5	7.1	20
369	Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. <i>Cancer Research</i> , 2014 , 74, 5386-96	10.1	20
368	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017 , 52, 34-40	4.4	20
367	A critical review of anagrelide therapy in essential thrombocythemia and related disorders. <i>Leukemia and Lymphoma</i> , 2005 , 46, 641-50	1.9	20
366	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012 , 120, 3138-3138	2.2	20

365	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016 , 128, 491-491	2.2	20
364	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 1930-1938	7.8	20
363	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017 , 102, 1439-1445	6.6	19
362	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. <i>Bone Marrow Transplantation</i> , 2014 , 49, 201-5	4.4	19
361	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020 , 34, 1135-1143	10.7	19
360	Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. <i>Haematologica</i> , 2005 , 90, 1650-4	6.6	19
359	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 549-554	7.1	18
358	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 20	7	18
357	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018 , 32, 1811-1815	10.7	18
356	Progenitor cell self-renewal and cyclic neutropenia. <i>Cell Proliferation</i> , 2009 , 42, 330-8	7.9	18
355	Somatic mutations and the hierarchy of hematopoiesis. <i>BioEssays</i> , 2010 , 32, 1003-8	4.1	18
354	Multiple mutant clones in blood rarely coexist. <i>Physical Review E</i> , 2008 , 77, 021915	2.4	18
353	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
352	Should tissue structure suppress or amplify selection to minimize cancer risk?. <i>Biology Direct</i> , 2016 , 11, 41	7.2	18
351	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020 , 10, 82	7	17
350	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018 , 8, 125	7	17
349	Stochastic dynamics and the evolution of mutations in stem cells. <i>BMC Biology</i> , 2011 , 9, 41	7.3	16
348	Acquired hematopoietic stem-cell disorders and mammalian size. <i>Blood</i> , 2007 , 110, 4120-2	2.2	16

347	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020 , 95, 310-315	7.1	16
346	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794	10.7	16
345	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018 , 2, 769-776	7.8	16
344	Detecting truly clonal alterations from multi-region profiling of tumours. <i>Scientific Reports</i> , 2017 , 7, 44994	19	15
343	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 811-814	10.7	15
342	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393	7.1	15
341	A Patient With Hereditary ATTR and a Novel AGel p.Ala578Pro Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1678-1682	6.4	15
340	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017 , 130, 1578-1584	2.2	15
339	In silico evolutionary dynamics of tumour virotherapy. <i>Integrative Biology (United Kingdom)</i> , 2010 , 2, 41-53	7	15
338	Modeling the architecture and dynamics of hematopoiesis. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2010 , 2, 235-244	6.6	15
337	Cyclic neutropenia in mammals. <i>American Journal of Hematology</i> , 2008 , 83, 920-1	7.1	15
336	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012 , 120, 201-201	2.2	15
335	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 1518-1523	7.1	15
334	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 888-895	4.5	14
333	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015 , 90, 888-91	7.1	14
332	Cyclic neutropenia in animals. <i>American Journal of Hematology</i> , 2009 , 84, 258-258	7.1	14
331	A microenvironment based model of antimitotic therapy of Gompertzian tumor growth. <i>Bulletin of Mathematical Biology</i> , 2007 , 69, 1691-708	2.1	14
330	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1156-8	4.4	14

329	In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics. <i>PLoS Computational Biology</i> , 2019 , 15, e1006773	5	13
328	Modelling hematopoiesis in health and disease. <i>Mathematical and Computer Modelling</i> , 2011 , 53, 1546-1557		13
327	Dynamics of haemopoiesis across mammals. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2008 , 275, 2389-92	4.4	13
326	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 455-464	6.4	13
325	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016 , 44, 32-9	2.7	13
324	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, E141-E143	7.1	13
323	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 106	7	13
322	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2360-2364	4.7	13
321	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 308-315	1.9	12
320	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 4	7	12
319	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2127-2132	4.7	12
318	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 56-58	6.4	12
317	Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. <i>Leukemia</i> , 2018 , 32, 719-728	10.7	12
316	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017 , 179, 98-105	4.5	12
315	Serum M-spike and transplant outcome in patients with multiple myeloma. <i>Cancer Science</i> , 2007 , 98, 1035-40	6.9	12
314	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 864-864	2.2	12
313	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 70	7	11
312	Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. <i>Journal of Gene Medicine</i> , 2012 , 14, 590-7	3.5	11

311	Evolutionary dynamics of chronic myeloid leukemia. <i>Genes and Cancer</i> , 2010 , 1, 309-15	2.9	11
310	Reproductive fitness advantage of BCR-ABL expressing leukemia cells. <i>Cancer Letters</i> , 2010 , 294, 43-8	9.9	11
309	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e108-e111	4.7	11
308	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019 , 33, 730-738	10.7	11
307	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 435-440	7.1	10
306	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017 , 281, 611-619	10.8	10
305	How many samples are needed to infer truly clonal mutations from heterogenous tumours?. <i>BMC Cancer</i> , 2019 , 19, 403	4.8	10
304	Estimation of Oncolytic Virus Populations within Tumors. <i>Cancer Research</i> , 2018 , 78, 5992-6000	10.1	10
303	A phase 1 trial of Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1372-1377	4.4	10
302	Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entry. <i>Journal of Virology</i> , 2010 , 84, 10913-7	6.6	10
301	The allometry of chronic myeloid leukemia. <i>Journal of Theoretical Biology</i> , 2009 , 259, 635-40	2.3	10
300	How best to use new therapies in multiple myeloma. <i>Blood Reviews</i> , 2010 , 24, 91-100	11.1	10
299	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013 , 122, 407-407	2.2	10
298	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020 , 34, 1472-1475	10.7	10
297	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020 , 95, 1280-1287	7.1	10
296	The invasion of de-differentiating cancer cells into hierarchical tissues. <i>PLoS Computational Biology</i> , 2019 , 15, e1007167	5	9
295	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018 , 182, 71-77	4.5	9
294	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018 , 93, 17-22	7.1	9

293	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1066-1071	7.1	9
292	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018 , 132, 598-598	2.2	9
291	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 6581-6588	12.9	9
290	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016 , 101, 1102-9	6.6	9
289	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 380-385	4.5	9
288	Preclinical development of CD126 CAR-T cells with broad antitumor activity. <i>Blood Cancer Journal</i> , 2021 , 11, 3	7	9
287	Imaging of Oncolytic Measles Virus Propagation with Single-Cell Resolution. <i>Molecular Therapy - Oncolytics</i> , 2019 , 12, 68-78	6.4	8
286	Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 349-357.e2	2	8
285	"Direct to Drug" screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 54	7	8
284	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018 , 103, 1229-1234	6.6	8
283	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 304-304	2.2	8
282	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015 , 126, 3050-3050	2.2	8
281	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021 , 11, 50	7	8
280	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1546-1577	6.4	8
279	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 587-594	4.4	7
278	Explaining the in vitro and in vivo differences in leukemia therapy. <i>Cell Cycle</i> , 2011 , 10, 1540-4	4.7	7
277	Optimized Treatment Schedules for Chronic Myeloid Leukemia. <i>PLoS Computational Biology</i> , 2016 , 12, e1005129	5	7
276	Replicative cellular age distributions in compartmentalized tissues. <i>Journal of the Royal Society Interface</i> , 2018 , 15,	4.1	7

275	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017 , 7, e569	7	6
274	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2039-2050	4.4	6
273	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1520-1525	4.7	6
272	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019 , 94, 751-756	7.1	6
271	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 637-642	7.1	6
270	Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria. <i>PLoS Computational Biology</i> , 2018 , 14, e1006133	5	6
269	In vivo and in silico studies on single versus multiple transplants for multiple myeloma. <i>Cancer Science</i> , 2007 , 98, 734-9	6.9	6
268	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012 , 120, 3972-3972	2.2	6
267	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020 , 95, 4-9	7.1	6
266	Ontogenic growth as the root of fundamental differences between childhood and adult cancer. <i>Stem Cells</i> , 2016 , 34, 543-50	5.8	6
265	T-cell large granular lymphocytic leukemia and plasma cell disorders. <i>Haematologica</i> , 2019 , 104, e108-e110	6.6	6
264	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021 , 96, 1131-1136	7.1	6
263	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1775-1779	4.4	5
262	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2132-2137	4.4	5
261	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018 , 32, 1421-1426	10.7	5
260	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019 , 54, 442-447	4.4	5
259	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 781-7	1.9	5
258	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1964-1964	2.2	5

257	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015 , 126, 1774-1774	2.2	5
256	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4197-4197	2.2	5
255	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016 , 128, 3337-3337	2.2	5
254	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 ,	10.7	5
253	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, E8-E10	7.1	5
252	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 53-56	2	5
251	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019 , 94, 424-430	7.1	5
250	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021 , 99, 707-715	9.9	5
249	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1144-1150	4.4	5
248	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021 , 195, 210-216	4.5	5
247	Emerging therapies for multiple myeloma. <i>Oncology</i> , 2009 , 23, 407-15	1.8	5
246	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1834-1839	6.4	4
245	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 1268-1272	10.7	4
244	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020 , 10, 52	7	4
243	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 326-333	4.4	4
242	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 101-102	2.7	4
241	A simple additive staging system for newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , 2022 , 12, 21	7	4
240	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019 , 134, 4106-4106	2.2	4

239	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019 , 134, 3140-3140	2.2	4
238	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. <i>Blood</i> , 2010 , 116, 370-370	2.2	4
237	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. <i>Blood</i> , 2011 , 118, 3963-3963	2.2	4
236	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 677-687	6.4	4
235	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021 , 35, 3604-3607	10.7	4
234	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021 , 35, 1428-1437	10.7	4
233	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 40-41	2.7	3
232	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017 , 92, E507-E512	7.1	3
231	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1297-1304	4.4	3
230	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 596-601	2	3
229	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2157-2159	4.7	3
228	Anagrelide: an update on its mechanisms of action and therapeutic potential. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 533-41	3.5	3
227	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020 , 136, 36-37	2.2	3
226	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013 , 122, 3119-3119	2.2	3
225	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015 , 126, 3177-3177	2.2	3
224	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016 , 128, 2968-2968	2.2	3
223	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3317-3317	2.2	3
222	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8002-8002	2.2	3

221	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1077-1081	4.4	3
220	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021 , 106, 354-361	3.8	3
219	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 330-337	7.1	3
218	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 155-161	4.4	3
217	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454	7.1	3
216	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021 , 11, 196	7	3
215	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1402-1405	4.7	2
214	Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e488-e491	2	2
213	Schnitzler syndrome: clinical features and histopathology. <i>Pathology and Laboratory Medicine International</i> , 2015 , 39	0	2
212	Evolutionary dynamics of two related malignant plasma cell lines. <i>Cell Cycle</i> , 2010 , 9, 3792-7	4.7	2
211	Reply: Evolutionary game theory: lessons and limitations, a cancer perspective. <i>British Journal of Cancer</i> , 2009 , 101, 2062-2063	8.7	2
210	The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.. <i>Annals of Hematology</i> , 2022 , 101, 251	3	2
209	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , 2022 ,	10.7	2
208	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019 , 134, 1872-1872	2.2	2
207	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019 , 134, 1846-1846	2.2	2
206	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4386-4386	2.2	2
205	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 52-53	2.2	2
204	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 30-31	2.2	2

203	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 12-13	2.2	2
202	Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2009 , 114, 615-615	2.2	2
201	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011 , 118, 2942-2942	2.2	2
200	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013 , 122, 3117-3117	2.2	2
199	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3210-3210	2.2	2
198	Thrombotic Microangiopathy in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 5317-5317	2.2	2
197	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2972-2972	2.2	2
196	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1639-1639	2.2	2
195	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3160-3160	2.2	2
194	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953	7.1	2
193	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 451-460.e2	2	2
192	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 589.e1-589.e6		2
191	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 928-935	4.4	2
190	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 44-45	2.7	1
189	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020 , 10, 124	7	1
188	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1170	7.1	1
187	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018 , 93, 1207-1210	7.1	1
186	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 183-188	2.7	1

185	Some dynamic aspects of hematopoietic stem cells. <i>Stem Cell Reviews and Reports</i> , 2008 , 4, 57-64	6.4	1
184	Genetic Targeting of Retroviral Vectors 2003 , 267-291		1
183	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). <i>Blood</i> , 2020 , 136, 29-30	2.2	1
182	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019 , 134, 72-72	2.2	1
181	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019 , 134, 4334-4334	2.2	1
180	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1905-1905	2.2	1
179	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020 , 136, 7-8	2.2	1
178	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 22-23	2.2	1
177	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. <i>Blood</i> , 2005 , 106, 5080-5080	2.2	1
176	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007 , 110, 2477-2477	2.2	1
175	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009 , 114, 956-956	2.2	1
174	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010 , 116, 3557-3557	2.2	1
173	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. <i>Blood</i> , 2010 , 116, 863-863	2.2	1
172	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2011 , 118, 2887-2887	2.2	1
171	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. <i>Blood</i> , 2011 , 118, 2950-2950	2.2	1
170	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 3095-3095	2.2	1
169	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 3981-3981	2.2	1
168	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 1858-1858	2.2	1

167	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012 , 120, 946-946	2.2	1
166	Survival Outcomes Of Very Young (. <i>Blood</i> , 2013 , 122, 2136-2136	2.2	1
165	Genomics Of Familial Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2803-2803	2.2	1
164	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013 , 122, 3095-3095	2.2	1
163	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015 , 126, 1830-1830	2.2	1
162	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2082-2082	2.2	1
161	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016 , 128, 3272-3272	2.2	1
160	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016 , 128, 3444-3444	2.2	1
159	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016 , 128, 4627-4627	2.2	1
158	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8015-8015	2.2	1
157	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021 , 11, 186	7	1
156	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
155	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , 2021 , 138, 3838-3838	2.2	1
154	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2021 ,	10.7	1
153	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.. <i>Blood</i> , 2005 , 106, 1164-1164	2.2	1
152	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018 , 132, 1606-1606	2.2	1
151	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.2	1
150	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018 , 132, 4152-4152	2.2	1

149	Therapy for relapsed multiple myeloma. <i>Panminerva Medica</i> , 2018 , 60, 174-184	2	1
148	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019 , 134, 1800-1800	2.2	1
147	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019 , 134, 5490-5490	2.2	1
146	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7552-7552	2.2	1
145	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. <i>Blood</i> , 2010 , 116, 2970-2970	2.2	1
144	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2010 , 116, 987-987	2.2	1
143	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020 , 95, E60-E62	7.1	1
142	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020 , 9, 8895-8901	4.8	1
141	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.9	1
140	Multistage feedback-driven compartmental dynamics of hematopoiesis. <i>iScience</i> , 2021 , 24, 102326	6.1	1
139	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021 , 62, 316-322	1.9	1
138	Quantitative imaging and dynamics of tumor therapy with viruses. <i>FEBS Journal</i> , 2021 , 288, 6273-6285	5.7	1
137	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021 , 11, 158	7	1
136	Death by fusion for acute leukemia cells. <i>Cancer Biology and Therapy</i> , 2010 , 9, 358-61	4.6	0
135	Work Productivity Loss and Quality of Life in Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States. <i>Blood</i> , 2020 , 136, 3-3	2.2	0
134	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020 , 136, 31-32	2.2	0
133	Kidney Transplant Outcomes of Patients With Multiple Myeloma.. <i>Kidney International Reports</i> , 2022 , 7, 752-762	4.1	0
132	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020 , 136, 48-49	2.2	0

131	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3760-3760	2.2	○
130	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 3774-3774	2.2	○
129	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021 , 138, 568-568	2.2	○
128	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019 , 134, 3171-3171	2.2	○
127	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021 , 6, 857-864	4.1	○
126	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 355-360	2	○
125	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 274-277	4.4	○
124	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021 , 96, E35-E38	7.1	○
123	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021 , 106, 433-436	3.8	○
122	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3011-3018	1.9	○
121	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 770.e1-770.e7		○
120	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , 2022 , 12, 59	7	○
119	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. <i>Blood Cancer Journal</i> , 2022 , 12, 62	7	○
118	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	○
117	Evolutionary Dynamics of Mutations in Hematopoietic Stem Cells and Beyond 2012 , 115-123		
116	Successful Cancer Treatment: Eradication of Cancer Stem Cells 2008 , 179-191		
115	Plasma membrane phospholipid labeling to estimate tumor burden and kinetics. <i>Cancer Biology and Therapy</i> , 2008 , 7, 748-9	4.6	
114	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 27-28	2.2	

113	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020 , 136, 44-45	2.2
112	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 15-16	2.2
111	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020 , 136, 14-15	2.2
110	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020 , 136, 6-7	2.2
109	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 21-22	2.2
108	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 21-22	2.2
107	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥75 Treated with Novel Agents. <i>Blood</i> , 2020 , 136, 12-13	2.2
106	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020 , 136, 37-38	2.2
105	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 41-42	2.2
104	Clinical Burden of Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States. <i>Blood</i> , 2020 , 136, 2-2	2.2
103	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020 , 136, 44-45	2.2
102	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021 , 138, 2707-2707	2.2
101	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNβ/IFNα). <i>Blood</i> , 2021 , 138, 1333-1333	2.2
100	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021 , 138, 2700-2700	2.2
99	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. <i>Blood</i> , 2021 , 138, 1617-1617	2.2
98	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021 , 138, 819-819	2.2
97	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021 , 138, 3805-3805	2.2
96	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1750-1750	2.2

95	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021 , 138, 3773-3773	2.2
94	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021 , 138, 3761-3761	2.2
93	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1632-1632	2.2
92	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1619-1619	2.2
91	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021 , 138, 543-543	2.2
90	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021 , 138, 1630-1630	2.2
89	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119	2.2
88	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2650-2650	2.2
87	Prognostic Diversity of Cytogenetic Lesions in Myelofibrosis with Myeloid Metaplasia: A Prospective Study of 88 Patients.. <i>Blood</i> , 2004 , 104, 1508-1508	2.2
86	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells.. <i>Blood</i> , 2004 , 104, 2392-2392	2.2
85	Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis.. <i>Blood</i> , 2005 , 106, 2585-2585	2.2
84	Microcytosis in Myelofibrosis with Myeloid Metaplasia: Prevalence and Clinical Correlates.. <i>Blood</i> , 2005 , 106, 4947-4947	2.2
83	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1165-1165	2.2
82	Single Versus Multiple Transplants for Multiple Myeloma: Insights from In Vivo and In Silico Studies.. <i>Blood</i> , 2006 , 108, 5452-5452	2.2
81	The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 5441-5441	2.2
80	Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.. <i>Blood</i> , 2006 , 108, 3629-3629	2.2
79	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1181-1181	2.2
78	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. <i>Blood</i> , 2007 , 110, 3608-3608	2.2

77	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1492-1492	2.2
76	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007 , 110, 2995-2995	2.2
75	Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry. <i>Blood</i> , 2018 , 132, 1038-1038	2.2
74	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1912-1912	2.2
73	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018 , 132, 3228-3228	2.2
72	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4449-4449	2.2
71	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2147-2147	2.2
70	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018 , 132, 3226-3226	2.2
69	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , 2018 , 132, 4613-4613	2.2
68	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , 2018 , 132, 4502-4502	2.2
67	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018 , 132, 5594-5594	2.2
66	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018 , 132, 3227-3227	2.2
65	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018 , 132, 5610-5610	2.2
64	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018 , 132, 3268-3268	2.2
63	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018 , 132, 3436-3436	2.2
62	T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. <i>Blood</i> , 2018 , 132, 5368-5368	2.2
61	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4615-4615	2.2
60	Patient-Reported Outcome Driven Case Management System for Hematology In Prospective Study. <i>Blood</i> , 2018 , 132, 719-719	2.2

- 59 Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. *Blood*, **2019**, 134, 4505-4505 2.2
- 58 Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). *Blood*, **2019**, 134, 5523-5523 2.2
- 57 Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. *Blood*, **2019**, 134, 1532-1532 2.2
- 56 Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. *Blood*, **2019**, 134, 3080-3080 2.2
- 55 Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 5833-5833 2.2
- 54 Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. *Blood*, **2019**, 134, 1904-1904 2.2
- 53 Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. *Blood*, **2019**, 134, 5532-5532 2.2
- 52 The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 2197-2197 2.2
- 51 Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. *Blood*, **2019**, 134, 2013-2013 2.2
- 50 N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292 2.2
- 49 Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. *Blood*, **2015**, 126, 3039-3039 2.2
- 48 AL Amyloidosis and Patient Reported Quality of Life. *Blood*, **2015**, 126, 3317-3317 2.2
- 47 The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. *Blood*, **2015**, 126, 3044-3044 2.2
- 46 The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. *Journal of Clinical Oncology*, **2016**, 34, 8033-8033 2.2
- 45 Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2016**, 34, 8053-8053 2.2
- 44 Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2016**, 34, 8017-8017 2.2
- 43 Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. *Journal of Clinical Oncology*, **2016**, 34, 8062-8062 2.2
- 42 Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. *Journal of Clinical Oncology*, **2016**, 34, 8016-8016 2.2

41	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016 , 128, 996-996	2.2
40	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016 , 128, 3273-3273	2.2
39	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016 , 128, 3251-3251	2.2
38	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016 , 128, 1810-1810	2.2
37	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016 , 128, 3306-3306	2.2
36	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1194-1194	2.2
35	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016 , 128, 3269-3269	2.2
34	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3338-3338	2.2
33	Outcome of Very Young (<40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016 , 128, 5576-5576	2.2
32	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2187-2187	2.2
31	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2267-2267	2.2
30	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. <i>Blood</i> , 2008 , 112, 2301-2301	2.2
29	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 3884-3884	2.2
28	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. <i>Blood</i> , 2010 , 116, 1965-1965	2.2
27	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010 , 116, 4518-4518	2.2
26	Risk Score at Diagnosis and the Dynamics of Response to TKI Therapy In Chronic Myeloid Leukemia.. <i>Blood</i> , 2010 , 116, 1236-1236	2.2
25	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010 , 116, 2253-2253	2.2
24	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1958-1958	2.2

23	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010 , 116, 3554-3554	2.2
22	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 4009-4009	2.2
21	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010 , 116, 3469-3469	2.2
20	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010 , 116, 3572-3572	2.2
19	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. <i>Blood</i> , 2011 , 118, 4120-4120	2.2
18	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2011 , 118, 3101-3101	2.2
17	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. <i>Blood</i> , 2011 , 118, 2992-2992	2.2
16	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. <i>Blood</i> , 2011 , 118, 2868-2868	2.2
15	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. <i>Blood</i> , 2011 , 118, 636-636	2.2
14	IgD Amyloidosis: An Unrecognized Entity. <i>Blood</i> , 2011 , 118, 5079-5079	2.2
13	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2012 , 120, 2973-2973	2.2
12	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012 , 120, 448-448	2.2
11	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 600-600	2.2
10	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012 , 120, 599-599	2.2
9	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1988-1988	2.2
8	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013 , 122, 2151-2151	2.2
7	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. <i>Blood</i> , 2013 , 122, 2794-2794	2.2
6	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1979-1979	2.2

- 5 Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. *Blood*, **2013**, 122, 3209-3209 2.2
- 4 Response to the Editor: On the Growth of Hematopoietic Stem Cells and Childhood Leukemias. *Stem Cells*, **2016**, 34, 2610 5.8
- 3 Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 309.e1-309.e5
- 2 Epstein Barr Virus-Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. *Kidney International Reports*, **2021**, 6, 2223-2227 4.1
- 1 Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**, 4.4